PathAI Launches AI-Powered Breast Cancer Biomarker Panel to Enhance Pathology Precision

PathAI announced the launch of the AIM-IHC Breast Panel, a set of advanced AI-assisted algorithms designed to quantify critical breast cancer biomarkers including HER2, ER, PR, and Ki-67. Available on the AISight Image Management System, this comprehensive panel provides partners with accurate, consistent scoring that enhances precision and streamlines workflow efficiency. The consolidation of these critical breast cancer biomarker algorithms into a single, pathologist-centric system directly addresses the need for standardized, reliable quantification assist tools to support pathologists.

The AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides accurate, consistent, zero-click scoring for HER2, ER, PR, and Ki-67 directly from routine immunohistochemistry images. With automated tissue segmentation and detection of on-slide controls, the panel classifies areas of invasive versus non-invasive cancer and provides overlays to support algorithmic scoring. This breast cancer-centric panel is designed for a pathologist-assist workflow, allowing users to better differentiate regions of interest, improve the accuracy of invasive cancer segmentation, and streamline tedious scoring processes.

The panel represents the latest addition to PathAI's expanding suite of AI-powered solutions on the AISight IMS, which serves as a central hub for managing pathology images and enabling seamless integration of various AI-driven tools for pathology labs. By centralizing workflows and offering a growing portfolio of applications, PathAI empowers pathologists and researchers to improve precision and efficiency within a unified, cloud-native platform. This continuous expansion underscores PathAI's commitment to providing comprehensive, reliable tools that enhance the field of pathology and ultimately improve patient outcomes.

Andrew Beck, CEO of PathAI, stated that the company is committed to advancing precision pathology with cutting-edge AI technology, empowering pathologists with tools to make more accurate, consistent, and efficient assessments. The AIM-IHC Breast Panel represents the latest step in PathAI's mission to enhance AI-powered scoring for key breast cancer biomarkers. The panel goes beyond HER2 by offering fast and accurate Ki-67 scoring, addressing the challenges of this emerging biomarker that has traditionally been time-consuming and labor-intensive. Pathologists no longer need to spend significant time manually counting cells or rely on imprecise approximations.

The panel's automated features, including classifying invasive cancer and generating percentage-based results for positive cancer cells, provide pathologists with the clarity needed to produce more accurate scoring. This introduction marks a significant step in PathAI's ongoing mission to enable precision pathology and empower pathologists with the latest AI-driven technologies. The release highlights PathAI's commitment to improving workflow efficiency, speed, and assessment accuracy, providing pathologists with comprehensive tools that streamline their workflow, accelerate decision-making, and reduce time spent on manual tasks in cancer diagnostic research.